- Walgreens Boots Alliance (WBA) is poised to release its fiscal fourth-quarter 2024 results on October 15.
- Analysts expect a significant drop in earnings per share (EPS) despite a slight revenue uptick.
- The company is navigating inflationary pressures and a competitive shift in the pharmacy landscape.
Walgreens Boots Alliance, the largest drugstore chain in the U.S., is set to disclose its fiscal fourth-quarter 2024 financial results pre-market on October 15. Industry observers are keenly watching as the company faces a critical juncture amid evolving market conditions.
While the anticipation of earnings stands at $0.36 per share—a sharp decline of 46.3% year-over-year—revenue is projected to inch up by 1.1% to $35.8 billion. This comes after the previous quarter's earnings fell by 37%, with a revenue rise of 2.6% to $36.4 billion.
Despite these challenges, Walgreens has been actively pursuing cost-cutting measures aimed at achieving $1 billion in savings this year. The strategic acquisition of VillageMD, including Summit Health, underscores its commitment to bolstering its healthcare business.
However, the company is not without its hurdles. Drug price inflation, coupled with the rise of online pharmacies, presents formidable challenges. Consumer sentiment remains tepid due to high inflation, further impacting retail sales.
According to people familiar with the matter, the stock's future trajectory will heavily depend on meeting or surpassing earnings expectations. A positive surprise could buoy the stock, yet any disappointment may exacerbate the 65% year-to-date decline.
Efforts to establish a visible roadmap for improved profitability and further strategic initiatives are critical for a turnaround. Attempts to reach Walgreens for comment on these developments were unsuccessful.
As the market awaits the forthcoming earnings release, stakeholders remain on edge, eagerly anticipating insights into the company's fiscal 2025 outlook and long-term profitability strategy.